Curing acute myelogenous leukemia: Still a major challenge

References 

1. Norton L, Simon R. Tumor size, sensitivity of therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307
   • MEDLINE
2. Vaughan WP, Burke PJ. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-B-d-arabinofuranosylcytosine in a rat model. Cancer Res. 1983;43:2005
   • MEDLINE
3. Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1B-d-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res. 1982;42:1587
   • MEDLINE
4. Rudnick S, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 1979;44:1189
   • CrossRef
5. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunroubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116
   • MEDLINE
6. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924
   • MEDLINE
7. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with cute myeloid leukemia. N Engl J Med. 1994;331:896
   • MEDLINE
   • CrossRef
8. Preisler HD, Raza A, Early A, Kirshner J, Brecher M, Freeman A, et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol. 1987;5:722
9. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood. 1992;80:2977
   • MEDLINE
10. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol. 1989;7:1260
11. Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, et al. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005;
12. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767